Citius Pharmaceuticals Inc
CTXR
Get informed when a big investor buys or sells
+ FollowMarket Cap$13.71M
Close$
$0.22
52.1% downside
Current Fair Value
52.1% downsideOvervalued by 52.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $13.71 Million |
|---|---|
| Enterprise Value | $3.88 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.38 |
| Beta | 1 |
| Outstanding Shares | 26,169,589 |
Return
| Return on Equity | -86.14% |
|---|---|
| Return on Assets | -40.34% |
| Return on Invested Capital | -65.91% |
Valuation & Multiples
| P/E Ratio | -0.24 |
|---|---|
| PEG | -0.66 |
| Price to Sales | - |
| Price to Book Ratio | 0.23 |
| Enterprise Value to Revenue | 0.55 |
| Enterprise Value to EBIT | -0.06 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.85 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$0.42
Average shareholder expectationRevenue Estimate
$19.57 M
Average shareholder expectationNext Earnings Call
Expected Date
December 17, 2026
EPS Estimate
$-0.41
Average shareholder expectationRevenue Estimate
$2.94 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 5.20%▲ 0.74% |
|---|---|
| Total Invested | $823,009▼ 8.24% |
| Investors Holding | 43▲ 3.00% |
ESG Score
No data
About Citius Pharmaceuticals Inc
10 employees
CEO: Myron Holubiak